Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

The company’s lead assets are potential first-in-class oral therapies – VE303, in a Phase 3 registrational trial for prevention of recurrent C. difficile infection, and VE202, in a Phase 2 trial for ...

Conclusion: Ocrelizumab-induced colitis is a rare, but severe adverse event ... Infectious screening was performed (stool culture, stool ova and parasite test, C. difficile testing) with negative ...

Introduction Clostridioides difficile (C.diff) is a gram positive anaerobic bacilli that can produce toxins leading to diarrhoea and/or colitis resulting in significant morbidity and mortality.

in a Phase 3 registrational trial for prevention of recurrent C. difficile infection, and VE202, in a Phase 2 trial for treatment of ulcerative colitis. Vedanta’s pipeline has been built using ...

Medically reviewed by Robert Burakoff, MD Irritable bowel syndrome (IBS) is a combination of digestive symptoms, including ...

Comment: IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), are chronic ... national and international guidelines currently in place for the treatment of C. difficile infection by FMT, and ...

In a major disappointment, the company decided in January 2023 to discontinue its phase III clinical trial for C. difficile infections. It will instead focus on developing treatments for ulcerative ...

Researchers once thought brewer's yeast might treat diarrhea caused by the bacterium Clostridioides difficile (also known as C. diff). Brewer's yeast may ... modulates host purine metabolism ...

Low-fiber fruits and vegetables, lean proteins, and foods rich in omega-3 fatty acids tend to be easier on an inflamed gut, ...

Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics, may be treated by stopping the inducing ...